Atlas Trials

A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML

Clinical trial NCT02708641 · COMPLETED

Trial details

NCT number
NCT02708641
Sponsor
Michael Boyiadzis
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Acute Myeloid Leukemia
Start date
2016-10-04
Primary completion
2020-06-11
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.